Jiapeng Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiapeng Lu has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
Wenyao Peng
National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Beijing, China
8 shared publications- Xi Li
National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
8 shared publications Siqi Lin
National Clinical Research Center for Cardiovascular Diseases Beijing, CN, Fuwai Hospital, Beijing, China
6 shared publicationsHao Yang
National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
5 shared publicationsLijuan Song
National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
5 shared publicationsXueke Bai
National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by BMJ in BMJ Global Health
- Vol. 11 (10) , e024235
Association between cigarette tax and the global burden of non-communicable diseases: a longitudinal ecological study in 193 countries
- 9 October 2026
- Published by BMJ in BMJ Global Health
- Vol. 11 (10) , e024235
Open AccessAssociation between cigarette tax and the global burden of non-communicable diseases: a longitudinal ecological study in 193 countries
- Open Access
- 27 January 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25 (1)
Association of HDL subclass components with all-cause and cardiovascular mortality: a prospective cohort study based on the ChinaHEART project
While the U-shaped association between high-density lipoprotein cholesterol (HDL-C) levels and the risk of all-cause and cardiovascular mortality is well-e
- 27 January 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25 (1)
Open AccessAssociation of HDL subclass components with all-cause and cardiovascular mortality: a prospective cohort study based on the ChinaHEART project
While the U-shaped association between high-density lipoprotein cholesterol (HDL-C) levels and the risk of all-cause and cardiovascular mortality is well-e
- Open Access
- 13 May 2025
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 22, 101007
Cost-effectiveness of cardiovascular risk assessment and management among adults with hypertension in China: A modelling study
- 13 May 2025
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 22, 101007
Open AccessCost-effectiveness of cardiovascular risk assessment and management among adults with hypertension in China: A modelling study
- Open Access
- 6 April 2025
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 57, 101544
Area-level socioeconomic inequalities in hypertension care cascade in China: a nationwide population-based study based on the ChinaHEART project
- 6 April 2025
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 57, 101544
Open AccessArea-level socioeconomic inequalities in hypertension care cascade in China: a nationwide population-based study based on the ChinaHEART project
- Open Access
Cardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort
Background Evidence of socioeconomic status (SES)-related health inequality is scarce in patients with cardiovascular diseases (CVDs) who need both lifestyle change and medical care, particularly in developing countries. Methods The study employed a nationwide population-based cohort design, covering all 31 provinces of Chinese mainland from September 2014 to March 2021. Participants aged 35–75 years with self-reported CVD diagnoses were included. Information on SES and lifestyle details were collected via a questionnaire, and the unequal mortality across SES groups and the mediating effects of lifestyles were explored. Results Among the 104 718 participants included, 27 943 (26.7%) were allocated to high SES, 35 802 (34.2%) were allocated to medium SES and 40 973 (39.1%) were allocated to low SES. During a mean follow-up of 48.9±18.9 months, 5010 deaths were recorded. Participants with low SES had a 65% (HR=1.65, 95% CI: 1.50 to 1.80) greater risk of all-cause death and a 95% (HR=1.95, 95% CI: 1.72 to 2.20) greater risk of CVD death in Chinese communities. A low SES with the worst lifestyle was associated with a significant increase in the risk of all-cause mortality by 172% (HR=2.72, 95% CI: 2.37 to 3.12) and CVD mortality by 218% (HR=3.18, 95% CI: 2.64 to 3.83) compared with a high SES with healthy lifestyle. The joint mediating effects of lifestyles on CVD mortality accounted for 19.6% (95%CI: 14.8% to 24.2%) of the excess mortality risk for individuals with low SES, and these effects varied by genders (p for interaction=0.013) and urbanity (p for interaction=0.004). Leisure-time physical activity was the strongest mediator, followed by dietary factors. For all-cause mortality, outcomes were similar to this. Conclusions Both SES-related health inequalities and lifestyle disparities should be comprehensively considered when caring for this population, and upstream structural interventions that integrate SES and lifestyle factors and are tailored to the target population are urgently needed. Trial registration number NCT02536456.
Open AccessCardiovascular disease-specific and all-cause mortality across socioeconomic status and lifestyles among patients with established cardiovascular disease in communities of China: data from a national population-based cohort
Background Evidence of socioeconomic status (SES)-related health inequality is scarce in patients with cardiovascular diseases (CVDs) who need both lifestyle change and medical care, particularly in developing countries. Methods The study employed a nationwide population-based cohort design, covering all 31 provinces of Chinese mainland from September 2014 to March 2021. Participants aged 35–75 years with self-reported CVD diagnoses were included. Information on SES and lifestyle details were collected via a questionnaire, and the unequal mortality across SES groups and the mediating effects of lifestyles were explored. Results Among the 104 718 participants included, 27 943 (26.7%) were allocated to high SES, 35 802 (34.2%) were allocated to medium SES and 40 973 (39.1%) were allocated to low SES. During a mean follow-up of 48.9±18.9 months, 5010 deaths were recorded. Participants with low SES had a 65% (HR=1.65, 95% CI: 1.50 to 1.80) greater risk of all-cause death and a 95% (HR=1.95, 95% CI: 1.72 to 2.20) greater risk of CVD death in Chinese communities. A low SES with the worst lifestyle was associated with a significant increase in the risk of all-cause mortality by 172% (HR=2.72, 95% CI: 2.37 to 3.12) and CVD mortality by 218% (HR=3.18, 95% CI: 2.64 to 3.83) compared with a high SES with healthy lifestyle. The joint mediating effects of lifestyles on CVD mortality accounted for 19.6% (95%CI: 14.8% to 24.2%) of the excess mortality risk for individuals with low SES, and these effects varied by genders (p for interaction=0.013) and urbanity (p for interaction=0.004). Leisure-time physical activity was the strongest mediator, followed by dietary factors. For all-cause mortality, outcomes were similar to this. Conclusions Both SES-related health inequalities and lifestyle disparities should be comprehensively considered when caring for this population, and upstream structural interventions that integrate SES and lifestyle factors and are tailored to the target population are urgently needed. Trial registration number NCT02536456.
- Open Access
Forecasting cardiovascular disease risk and burden in China from 2020 to 2030: a simulation study based on a nationwide cohort
Background Cardiovascular disease (CVD) remains a significant public health challenge in China. This study aimed to project the burden of CVD from 2020 to 2030 using a nationwide cohort and to simulate the potential impact of various control measures on morbidity and mortality. Methods An agent-based model was employed to simulate annual CVD incidence and mortality from 2021 to 2030. The effects of different prevention and treatment interventions, modelled on international strategies, were also explored. Results The study included 106 259 participants. The annual CVD incidence rate is projected to increase from 0.74% in 2021 to 0.97% by 2030, with age-standardised and sex-standardised rates rising from 0.71% to 0.96%. CVD mortality is expected to rise from 0.39% in 2021 to 0.46% in 2024, after which it will stabilise at 0.44% by 2030. Community-based interventions and improved access to inpatient care are predicted to reduce the projected burden of CVD significantly. Conclusions The incidence of CVD in China is projected to increase steadily over the next decade, while mortality will plateau after 2024. Comprehensive interventions, including community-based screenings and enhanced healthcare access, could significantly mitigate the CVD burden. Trial registration number NCT02536456.
Open AccessForecasting cardiovascular disease risk and burden in China from 2020 to 2030: a simulation study based on a nationwide cohort
Background Cardiovascular disease (CVD) remains a significant public health challenge in China. This study aimed to project the burden of CVD from 2020 to 2030 using a nationwide cohort and to simulate the potential impact of various control measures on morbidity and mortality. Methods An agent-based model was employed to simulate annual CVD incidence and mortality from 2021 to 2030. The effects of different prevention and treatment interventions, modelled on international strategies, were also explored. Results The study included 106 259 participants. The annual CVD incidence rate is projected to increase from 0.74% in 2021 to 0.97% by 2030, with age-standardised and sex-standardised rates rising from 0.71% to 0.96%. CVD mortality is expected to rise from 0.39% in 2021 to 0.46% in 2024, after which it will stabilise at 0.44% by 2030. Community-based interventions and improved access to inpatient care are predicted to reduce the projected burden of CVD significantly. Conclusions The incidence of CVD in China is projected to increase steadily over the next decade, while mortality will plateau after 2024. Comprehensive interventions, including community-based screenings and enhanced healthcare access, could significantly mitigate the CVD burden. Trial registration number NCT02536456.
- Open Access
- 15 October 2024
- Published by Elsevier in The Lancet Public Health
- Vol. 9 (12) , e1014-e1024
Area-level socioeconomic inequalities in mortality in China: a nationwide cohort study based on the ChinaHEART project
- 15 October 2024
- Published by Elsevier in The Lancet Public Health
- Vol. 9 (12) , e1014-e1024
Open AccessArea-level socioeconomic inequalities in mortality in China: a nationwide cohort study based on the ChinaHEART project
- Top Cited PapersOpen Access
- 15 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (20) , e036669
Predictive Value of Life's Crucial 9 for Cardiovascular and All‐Cause Mortality: A Prospective Cohort Study From the NHANES 2007 to 2018
Background: The predictive value of Life's Crucial 9 (LC9), a recently proposed cardiovascular health risk score combining psychological health and Life's Essential 8 (LE8), remains unclear. Methods and Results: In this cohort study, we included 16 290 adults without cardiovascular disease from the 2007 to 2018 cycles of NHANES (National Health and Nutrition Examination Survey). The LC9 was the mean of the LE8 score and the depression score, which represented a dimension of psychological health. The study outcomes were cardiovascular and all‐cause mortality. Cox proportional hazard models were fitted to estimate the association of LC9 and LE8 scores with outcomes. The differences in Harrell's concordance index, net reclassification improvement index, and integrated discrimination improvement were calculated to assess the predictive ability of the depression score in addition to the LE8 score. During a median follow‐up of 7.08 years, 879 (5.40%) participants died, and 242 (1.49%) died from cardiovascular disease. The adjusted hazard ratio (HR) of per LE8 10‐score increase for cardiovascular mortality was 0.80 (95% CI, 0.72–0.88; P P P =0.30), the net reclassification improvement index was 10.6% (95% CI, −7.6% to 18.9%; P =0.073), and the IDI was 0.002 (95% CI, 0.000–0.007; P =0.033). The results for all‐cause mortality showed similar patterns. Conclusions: Compared with the LE8, the improvement in the predictive value of LC9 was negligible. It may not be necessary to add a depression score to the current cardiovascular health score.
- 15 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (20) , e036669
Top Cited PapersOpen AccessPredictive Value of Life's Crucial 9 for Cardiovascular and All‐Cause Mortality: A Prospective Cohort Study From the NHANES 2007 to 2018
Background: The predictive value of Life's Crucial 9 (LC9), a recently proposed cardiovascular health risk score combining psychological health and Life's Essential 8 (LE8), remains unclear. Methods and Results: In this cohort study, we included 16 290 adults without cardiovascular disease from the 2007 to 2018 cycles of NHANES (National Health and Nutrition Examination Survey). The LC9 was the mean of the LE8 score and the depression score, which represented a dimension of psychological health. The study outcomes were cardiovascular and all‐cause mortality. Cox proportional hazard models were fitted to estimate the association of LC9 and LE8 scores with outcomes. The differences in Harrell's concordance index, net reclassification improvement index, and integrated discrimination improvement were calculated to assess the predictive ability of the depression score in addition to the LE8 score. During a median follow‐up of 7.08 years, 879 (5.40%) participants died, and 242 (1.49%) died from cardiovascular disease. The adjusted hazard ratio (HR) of per LE8 10‐score increase for cardiovascular mortality was 0.80 (95% CI, 0.72–0.88; P P P =0.30), the net reclassification improvement index was 10.6% (95% CI, −7.6% to 18.9%; P =0.073), and the IDI was 0.002 (95% CI, 0.000–0.007; P =0.033). The results for all‐cause mortality showed similar patterns. Conclusions: Compared with the LE8, the improvement in the predictive value of LC9 was negligible. It may not be necessary to add a depression score to the current cardiovascular health score.
- 1 June 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (6) , e011118
Prognostic Value of a Multi-mRNA Signature for 1-Year All-Cause Death in Hospitalized Patients With Heart Failure With a Preserved Ejection Fraction
BACKGROUND: Heart failure with preserved ejection fraction is a major global public health problem, while effective risk stratification tools are still lacking. We sought to construct a multi-mRNA signature to predict 1-year all-cause death. METHODS: We selected 30 patients with heart failure with preserved ejection fraction who died during 1-year follow-up and 30 who survived in the discovery set. One hundred seventy-one and 120 patients with heart failure with preserved ejection fraction were randomly selected as a test set and a validation set, respectively. We performed mRNA microarrays in all patients. RESULTS: We constructed a 5-mRNA signature for predicting 1-year all-cause death. The scores of the 5-mRNA signature were significantly associated with the 1-year risk of all-cause death in both the test set (hazard ratio, 2.72 [95% CI, 1.98–3.74]; P P P <0.001). CONCLUSIONS: The 5-mRNA signature is a promising predictive tool for 1-year all-cause death and shows improved prognostic power over the established risk scores and NT-proBNP in patients with heart failure with preserved ejection fraction.
- 1 June 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (6) , e011118
Prognostic Value of a Multi-mRNA Signature for 1-Year All-Cause Death in Hospitalized Patients With Heart Failure With a Preserved Ejection Fraction
BACKGROUND: Heart failure with preserved ejection fraction is a major global public health problem, while effective risk stratification tools are still lacking. We sought to construct a multi-mRNA signature to predict 1-year all-cause death. METHODS: We selected 30 patients with heart failure with preserved ejection fraction who died during 1-year follow-up and 30 who survived in the discovery set. One hundred seventy-one and 120 patients with heart failure with preserved ejection fraction were randomly selected as a test set and a validation set, respectively. We performed mRNA microarrays in all patients. RESULTS: We constructed a 5-mRNA signature for predicting 1-year all-cause death. The scores of the 5-mRNA signature were significantly associated with the 1-year risk of all-cause death in both the test set (hazard ratio, 2.72 [95% CI, 1.98–3.74]; P P P <0.001). CONCLUSIONS: The 5-mRNA signature is a promising predictive tool for 1-year all-cause death and shows improved prognostic power over the established risk scores and NT-proBNP in patients with heart failure with preserved ejection fraction.
- 16 April 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (16) , 1258-1267
Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial
BACKGROUND: Postprocedural anticoagulation (PPA) is frequently administered after primary percutaneous coronary intervention in ST-segment–elevation myocardial infarction, although no conclusive data support this practice. METHODS: The RIGHT trial (Comparison of Anticoagulation Prolongation vs no Anticoagulation in STEMI Patients After Primary PCI) was an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled, superiority trial conducted at 53 centers in China. Patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention were randomly assigned by center to receive low-dose PPA or matching placebo for at least 48 hours. Before trial initiation, each center selected 1 of 3 PPA regimens (40 mg of enoxaparin once daily subcutaneously; 10 U·kg·h of unfractionated heparin intravenously, adjusted to maintain activated clotting time between 150 and 220 seconds; or 0.2 mg·kg·h of bivalirudin intravenously). The primary efficacy objective was to demonstrate superiority of PPA to reduce the primary efficacy end point of all-cause death, nonfatal myocardial infarction, nonfatal stroke, stent thrombosis (definite), or urgent revascularization (any vessel) within 30 days. The key secondary objective was to evaluate the effect of each specific anticoagulation regimen (enoxaparin, unfractionated heparin, or bivalirudin) on the primary efficacy end point. The primary safety end point was Bleeding Academic Research Consortium 3 to 5 bleeding at 30 days. RESULTS: Between January 10, 2019, and September 18, 2021, a total of 2989 patients were randomized. The primary efficacy end point occurred in 37 patients (2.5%) in both the PPA and placebo groups (hazard ratio, 1.00 [95% CI, 0.63 to 1.57]). The incidence of Bleeding Academic Research Consortium 3 to 5 bleeding did not differ between the PPA and placebo groups (8 [0.5%] vs 11 [0.7%] patients; hazard ratio, 0.74 [95% CI, 0.30 to 1.83]). CONCLUSIONS: Routine PPA after primary percutaneous coronary intervention was safe but did not reduce 30-day ischemic events. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03664180.
- 16 April 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (16) , 1258-1267
Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial
BACKGROUND: Postprocedural anticoagulation (PPA) is frequently administered after primary percutaneous coronary intervention in ST-segment–elevation myocardial infarction, although no conclusive data support this practice. METHODS: The RIGHT trial (Comparison of Anticoagulation Prolongation vs no Anticoagulation in STEMI Patients After Primary PCI) was an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled, superiority trial conducted at 53 centers in China. Patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention were randomly assigned by center to receive low-dose PPA or matching placebo for at least 48 hours. Before trial initiation, each center selected 1 of 3 PPA regimens (40 mg of enoxaparin once daily subcutaneously; 10 U·kg·h of unfractionated heparin intravenously, adjusted to maintain activated clotting time between 150 and 220 seconds; or 0.2 mg·kg·h of bivalirudin intravenously). The primary efficacy objective was to demonstrate superiority of PPA to reduce the primary efficacy end point of all-cause death, nonfatal myocardial infarction, nonfatal stroke, stent thrombosis (definite), or urgent revascularization (any vessel) within 30 days. The key secondary objective was to evaluate the effect of each specific anticoagulation regimen (enoxaparin, unfractionated heparin, or bivalirudin) on the primary efficacy end point. The primary safety end point was Bleeding Academic Research Consortium 3 to 5 bleeding at 30 days. RESULTS: Between January 10, 2019, and September 18, 2021, a total of 2989 patients were randomized. The primary efficacy end point occurred in 37 patients (2.5%) in both the PPA and placebo groups (hazard ratio, 1.00 [95% CI, 0.63 to 1.57]). The incidence of Bleeding Academic Research Consortium 3 to 5 bleeding did not differ between the PPA and placebo groups (8 [0.5%] vs 11 [0.7%] patients; hazard ratio, 0.74 [95% CI, 0.30 to 1.83]). CONCLUSIONS: Routine PPA after primary percutaneous coronary intervention was safe but did not reduce 30-day ischemic events. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03664180.